Goldman Sachs Reiterates Top Rating on Alexion Pharmaceuticals (ALXN) After Meetings

Goldman Sachs reiterated its Conviction Buy List rating on Alexion Pharmaceuticals (NASDAQ: ALXN) after a visit, citing continued outperformance driven by upside to estimates and positive catalysts.

The firm highlights that management sees Soliris's launch in aHUS going well, which will be the next driver of growth. Also, proof of concept data for Soliris in neuromyelitis optica could come as early as April. This is a a key focus as it could be the next big indication, the firm notes.

Management displayed high confidence in potential of asfotase alfa. They see dry AMD as outside their area of focus and Management allayed investor concerns on potential competition. "They do not see a C1 esterase inhibitor as either scientifically or commercially viable for PNH."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $84.54 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics